179 related articles for article (PubMed ID: 30150464)
1. Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline.
Newman JV; Zhou J; Izmailyan S; Tsai L
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150464
[TBL] [Abstract][Full Text] [Related]
2. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.
Zhanel GG; Cheung D; Adam H; Zelenitsky S; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty A; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2016 Apr; 76(5):567-88. PubMed ID: 26863149
[TBL] [Abstract][Full Text] [Related]
3. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.
Solomkin J; Evans D; Slepavicius A; Lee P; Marsh A; Tsai L; Sutcliffe JA; Horn P
JAMA Surg; 2017 Mar; 152(3):224-232. PubMed ID: 27851857
[TBL] [Abstract][Full Text] [Related]
4. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections.
Solomkin JS; Ramesh MK; Cesnauskas G; Novikovs N; Stefanova P; Sutcliffe JA; Walpole SM; Horn PT
Antimicrob Agents Chemother; 2014; 58(4):1847-54. PubMed ID: 24342651
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits.
Petraitis V; Petraitiene R; Maung BBW; Khan F; Alisauskaite I; Olesky M; Newman J; Mutlib A; Niu X; Satlin M; Singh RS; Derendorf H; Walsh TJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941646
[TBL] [Abstract][Full Text] [Related]
6. Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects.
Newman JV; Zhou J; Izmailyan S; Tsai L
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559132
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects.
Cass RT; Brooks CD; Havrilla NA; Tack KJ; Borin MT; Young D; Bruss JB
Antimicrob Agents Chemother; 2011 Dec; 55(12):5874-80. PubMed ID: 21911572
[TBL] [Abstract][Full Text] [Related]
8. Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis.
Thabit AK; Monogue ML; Newman JV; Nicolau DP
Int J Antimicrob Agents; 2018 May; 51(5):727-732. PubMed ID: 29325762
[TBL] [Abstract][Full Text] [Related]
9. Eravacycline: A Review in Complicated Intra-Abdominal Infections.
Scott LJ
Drugs; 2019 Feb; 79(3):315-324. PubMed ID: 30783960
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects.
Eckburg PB; Lister T; Walpole S; Keutzer T; Utley L; Tomayko J; Kopp E; Farinola N; Coleman S
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262767
[TBL] [Abstract][Full Text] [Related]
11. Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative SPR206.
Bruss J; Lister T; Gupta VK; Stone E; Morelli L; Lei Y; Melnick D
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0073921. PubMed ID: 34339267
[TBL] [Abstract][Full Text] [Related]
12. Eravacycline for the treatment of complicated intra-abdominal infections.
Montravers P; Zappella N; Tran-Dinh A
Expert Rev Anti Infect Ther; 2019 Nov; 17(11):851-863. PubMed ID: 31622119
[No Abstract] [Full Text] [Related]
13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Eravacycline: A Novel Fluorocycline.
Alosaimy S; Abdul-Mutakabbir JC; Kebriaei R; Jorgensen SCJ; Rybak MJ
Pharmacotherapy; 2020 Mar; 40(3):221-238. PubMed ID: 31944332
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.
Muralidharan G; Micalizzi M; Speth J; Raible D; Troy S
Antimicrob Agents Chemother; 2005 Jan; 49(1):220-9. PubMed ID: 15616299
[TBL] [Abstract][Full Text] [Related]
16.
Zhao M; Lepak AJ; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416552
[TBL] [Abstract][Full Text] [Related]
17. Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens.
Bundrant LA; Tzanis E; Garrity-Ryan L; Bai S; Chitra S; Manley A; Villano S
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180524
[TBL] [Abstract][Full Text] [Related]
18. Eravacycline for the treatment of patients with bacterial infections.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2018 Apr; 54(4):245-254. PubMed ID: 29869646
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects.
Saisho Y; Katsube T; White S; Fukase H; Shimada J
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311072
[TBL] [Abstract][Full Text] [Related]
20. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.
Solomkin JS; Gardovskis J; Lawrence K; Montravers P; Sway A; Evans D; Tsai L
Clin Infect Dis; 2019 Aug; 69(6):921-929. PubMed ID: 30561562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
